Paper Details

  1. Home
  2. Paper Details

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

Author: Abou-AlfaGhassan K, ArnedosMónica, BergerMichael F, BoradMitesh, BrañaIrene, ClearyJames M, DiPrimeoDaniel, Duygu SelcukluS, EliLisa D, FordJames M, FountzilasChristos, HardingJames J, JhaveriKomal, LoiSherene, Meric-BernstamFunda, MorenoVictor, MurphyJessica J, ParkHaeseong, Piha-PaulSarina A, QuinnDavid I, SavinCasey, ShahRonak H, ShapiroGeoffrey I, SolitDavid B, SpanggaardIben, StemmerSalomon M, ZhangJie, de la FouchardiereChristelle

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Neratinib, a pan-HER tyrosine kinase inhibitor, showed some antitumor activity in patients with biliary tract cancers (BTCs) harboring HER2 mutations, but the primary endpoint of the SUMMIT trial was not met. Diarrhoea was the most common adverse event.
Paper Details　
Original Abstract of the Article :
HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in HER2-mutant tumours. SUMMIT is an open-label, single-arm, multi-cohort, phase...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902444/

データ提供：米国国立医学図書館（NLM）

Neratinib: A Potential Treatment for HER2-Mutant Biliary Tract Cancers

Biliary tract cancers are a complex group of malignancies with limited treatment options. This research investigates the efficacy of neratinib, a tyrosine kinase inhibitor, in patients with advanced biliary tract cancers harboring HER2 mutations. The study examines the response rate, safety, and tolerability of neratinib in this specific patient population.

Neratinib: A Promising Approach for HER2-Mutant Cancers

While neratinib demonstrated some anti-tumor activity in patients with HER2-mutant biliary tract cancers, the primary endpoint of the study was not met. This highlights the need for further research to explore potential combinations of therapies that may be more effective.

Biliary Tract Cancers: A Difficult Battle

Biliary tract cancers are often diagnosed at later stages, making treatment more challenging. The study's findings underscore the need for continued research into novel treatments for these cancers, aiming to improve outcomes for patients.

Dr.Camel's Conclusion

Fighting biliary tract cancers can be a challenging journey, akin to navigating a treacherous desert. This study offers a glimpse into the potential of neratinib for HER2-mutant cancers, encouraging further exploration of this promising avenue for treatment development.

Date :
  1. Date Completed 2023-02-08
  2. Date Revised 2023-04-12
Further Info :

Pubmed ID

36746967

DOI: Digital Object Identifier

PMC9902444

Related Literature

Article Analysis
・Effects of neratinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.